Scion Amit Patni Re-enters the Operating Arena with Raay Neo Pharma, Reviving Legacy Through Pharma Bet

The company has already developed a portfolio of around 100 SKUs across key therapy areas, including cardiology, diabetes, respiratory, gastroenterology, and central nervous system disorders.

Scion Amit Patni has re-entered the business-building space with the launch of Raay Neo Pharma, headquartered in Mumbai, signalling a shift from investment-led activities to creating a scalable pharmaceutical enterprise.

The development draws from the legacy of the Patni family, which played a formative role in shaping India’s IT outsourcing ecosystem. Patni Computer Systems, founded in the 1970s, was among the earliest firms to operationalise offshore delivery, serving global clients and nurturing talent that later built Infosys.

The company scaled significantly before being acquired in 2011 and eventually integrated into Capgemini, marking the end of its independent journey.

With Raay Neo Pharma, Amit Patni is taking a greenfield approach. The company has already developed a portfolio of around 100 SKUs across key therapy areas, including cardiology, diabetes, respiratory, gastroenterology, and central nervous system disorders.

It plans to expand into sports medicine while also focusing on nutraceuticals and general wellness products.

“We have developed about 100 SKUs of a complete range of branded generic medicines in cardiology, diabetes, respiratory, gastro and CNS specialities in the past few months, and soon will add sports medicine. Our main focus will be on branded generics, nutraceuticals, and general wellness products,” Amit Patni said.

The company is initially relying on contract manufacturing through established partners while building its market presence. It has deployed approximately 300 medical representatives across 11 states and is preparing for a wider national rollout, with plans to expand coverage to over 20 states and increase its field force to more than 400.

Parallel efforts are underway to in-license established brands and explore exports in unregulated international markets.

The leadership team includes Amit Patni, his daughter Aakriti Patni, and finance professional Ritu Dhariwal, supported by senior hires from established pharmaceutical companies.

Amit Patni, who has spent over three decades across technology, investments, and advisory roles, has previously been associated with ventures such as RAAY Global Investments, Nirvana Venture Advisors, and The Hive India.

Stay tuned for more such updates on Digital Health News